SEATTLE, July 11, 2016 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing treatments for life-threatening inherited liver diseases in children, today announced that the company will present data evaluating its mRNA Hybrid Technology platform at the 43rd Annual Meeting & Exposition of the Controlled Release Society (CRS) taking place July 17-20, 2016 in Seattle.
Presentation details are as follows:
Title: "Targeted mRNA Delivery to the Liver for Intracellular Enzyme Replacement Therapy (i-ERT)"
Presenter: Pierrot Harvie, Ph.D., associate director of Formulations at PhaseRx Session: Pre-conference Nanomedicines Symposium, 11:10 a.m. PDT on Saturday, July 16, 2016
Location: Washington Athletic Club, Crystal Ballroom, 3rd Floor
This presentation will be live streamed at https://www.youtube.com/watch?v=NAsmSxpMy2E.
Title: "Targeted Di-Block Polymers Deliver mRNA to the Liver for the Treatment of Urea Cycle Disorder"
Presenter: Debashish Roy, Ph.D., scientist II of Chemistry at PhaseRx
Poster on display: July 17-19, 2016
Location: Exhibit Hall, Washington State Convention Center Exhibit Hall, Room 4AB on level 4
About PhaseRx
PhaseRx is a leading biopharmaceutical company dedicated to developing products for the treatment of children with inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy (i-ERT). PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of twelve and are characterized by the body's inability to remove ammonia from the blood. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA TechnologyTM platform. PhaseRx is headquartered in Seattle. For more information, please visit www.phaserx.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/phaserx-announces-targeted-mrna-data-presentations-at-the-controlled-release-society-annual-meeting-and-exposition-300296346.html
SOURCE PhaseRx, Inc.
